$PGEN

Tennant Phil sold $132K of PGEN

Tennant Phil (Chief Commercial Officer) sold 30,272 shares of PRECIGEN, INC. (PGEN) at $4.36 ($0.13M total) on 2026-05-28.

Original reporting
SEC EDGAR · Tennant Phil
Published Jun 1, 2026, 8:28 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 1, 2026, 8:39 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PGEN
Bearish
medium confidence
Mentioned
$PGEN
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PGENBearishLow
01

Why it matters

The disclosure may slightly influence short-term sentiment among traders monitoring insider behavior, but it does not provide new company fundamentals (no guidance, trial, deal, or regulatory update).

02

Market read

Traders may treat this as a mild negative sentiment datapoint; conviction should be low without corroborating fundamental news.

03

What to watch

No 10b5-1 plan is noted, but the filing still lacks context (e.g., tax events, planned compensation exercises, or prior commitments) that would clarify informativeness.

Relevance 6/10Novelty 6/10Timing: Filed 2026-06-01; reflects sale executed 2026-05-28.

Background

SEC Form 4 reports insider transactions; this filing discloses a Chief Commercial Officer’s direct open-market sale of Precigen shares.

Company-level read

Ticker impact

$PGENBearishMedium confidence
Context

Pre-arranged 10b5-1 plan was not used; CCO Phil Tennant sold 30,272 shares of Precigen at $4.36 on 2026-05-28.

Expected impact

Likely limited near-term impact; any effect should fade unless followed by additional insider selling or new fundamentals.

Evidence & confidence

This is an SEC Form 4 transaction disclosure with no accompanying company-specific operational or financial update; insider sales often have non-informational explanations.

Market effects

Minimal; this is company-specific insider activity with no stated sector-wide development.

None indicated.

None indicated.

Counterpoint

The sale was an open-market transaction and may be driven by diversification, taxes, or pre-existing personal liquidity needs rather than bearish expectations.

Key entities

  • PRECIGEN, INC.

    Company whose insider transaction was disclosed on SEC Form 4.

  • Tennant Phil

    Chief Commercial Officer who sold 30,272 shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PGENMedAI 8/10

Precigen (PGEN) Gets FDA Recognition. Can it Cut the Cost of Developing New Drugs?

Precigen (PGEN) received FDA Platform Technology Designation for AdenoVerse, the technology behind PAPZIMEOS. The designation may reduce development costs for future drugs, including PRGN-2009, an investigational cancer treatment. Management expects benefits but has not quantified cost savings or timelines. The FDA's draft guidance outlines potential benefits, but Precigen must provide supporting evidence for reuse of prior data. Hedge fund sentiment showed a slight decrease in holdings.

$PGENHighAI 8/10

Precigen Receives FDA Platform Technology Designation for AdenoVerse Platform

Precigen, Inc. (PGEN) announced that the FDA granted platform technology designation to its AdenoVerse® immunotherapeutic platform, used in its commercial product PAPZIMEOS®. This designation may accelerate the development of future therapies by leveraging existing data and reducing duplicative work. The company's CEO highlighted the potential benefits for its clinical portfolio, including PRGN-2009 for HPV-associated cancers.

$MRNAHighAI 9/10

After Moderna’s Big News, Here Are Three Biotechs to Watch

Moderna (MRNA) and Merck (MRK) rose sharply after positive Phase 3 trial data for a skin cancer therapy. Biotech sector, up 40% YTD, saw gains. Aurinia (AUPH) settled litigation with Teva (TEVA), removing uncertainty. Ocular (OCUL) received positive analyst ratings. Precigen (PGEN) reported strong Q2 revenue and expects cash flow breakeven by year-end.

$PGENMed

Precigen (PGEN) Q2 2026 Earnings Call Transcript

Precigen (PGEN) reported Q2 2026 PAPZIMEOS net revenue of $53.1 million, up 145.8% sequentially from $21.6 million, and first quarterly net income of $20.1 million, or $0.05 per diluted share. Gross margin was 95% but management expects normalization to high 80% to low 90%. Cash and investments were $38.7 million at June 30, 2026.

$PGENMed

Precigen Reports Second Quarter 2026 Financial Results Highlighted by Accelerating PAPZIMEOS Revenue Growth

PRECIGEN, INC. (PGEN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Precigen Reports Second Quarter 2026 Financial Results Highlighted by Accelerating PAPZIMEOS Revenue Growth · PAPZIMEOS ® net revenue of $53.1 million in the second quarter of 2026, more than double the prior quarter, reflects accelerating commercial momentum and bro